BackContineum Therapeutics Overview
Contineum Therapeutics Inc. - Ordinary Shares - Class A

Contineum Therapeutics Target Price

See Contineum Therapeutics's analyst price targets ($16) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$15.3

Average Target Price

$16.004.6% upside

1 analysts in the last 4 months

High: $16 | Low: $16

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-05-14Morgan Stanley$164.6% upsideOpen
2026-01-08Morgan Stanley$148.5% downsideOpen
2025-11-24Robert W. Baird$148.5% downsideOpen
2025-11-21RBC CapitalBrian Abrahams$2243.8% upsideOpen
2025-09-25Leerink Partners$2030.7% upsideOpen
2025-03-07Robert W. Baird$164.6% upsideOpen
2024-10-21Robert W. BairdJoel Beatty$32109.2% upsideOpen
2024-04-30RBC CapitalBrian Abrahams$3096.1% upsideOpen
2024-04-30Stifel NicolausPaul Matteis$2989.5% upsideOpen

Contineum Therapeutics (CTNM) FAQ

Contineum Therapeutics's target price stands at $16. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $16 for CTNM implies 4.6% upside versus today's price ($15.3). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Contineum Therapeutics's target price evolved across reporting periods, while the comparison chart places CTNM next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.